Pancreatic Cancer Research

ResearcherAlbert Einstein College of MedicineActive in the last 2 years

Benson Chellakkan Selvanesan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8013-1294; OpenAlex author ID A5059172875. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 8

  1. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  2. The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-25-0278↗
  3. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  4. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  5. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
  6. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Co-author DOI 10.1126/scitranslmed.abc1600↗
  7. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. Co-author DOI 10.1136/jitc-2020-001250↗
  8. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. First author DOI 10.18632/oncotarget.15117↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 5 shared papers, 2025–2026 · strength 1.03
  2. Huamin Wang · 2 shared papers, 2026 · strength 0.49
  3. Thomas C. Caffrey · 2 shared papers, 2025–2026 · strength 0.40
  4. Jimin Min · 2 shared papers, 2025–2026 · strength 0.40
  5. Vincent Bernard · 2 shared papers, 2025–2026 · strength 0.40
  6. Michael Anthony Hollingsworth · 2 shared papers, 2025–2026 · strength 0.40
  7. Paul M. Grandgenett · 2 shared papers, 2025–2026 · strength 0.40
  8. Fredrik I. Thege · 2 shared papers, 2025 · strength 0.33
  9. Paola A. Guerrero · 2 shared papers, 2025 · strength 0.33
  10. Claudia Gravekamp · 3 shared papers, 2017–2022 · strength 0.30
  11. MennatAllah Shaheen · 1 shared paper, 2026 · strength 0.27
  12. Ching-Fei Li · 1 shared paper, 2026 · strength 0.27
  13. Haoqiang Ying · 1 shared paper, 2026 · strength 0.27
  14. Bidyut Ghosh · 1 shared paper, 2026 · strength 0.27
  15. Seong-Woo Bae · 1 shared paper, 2026 · strength 0.22
  16. Riccardo Ballarò · 1 shared paper, 2026 · strength 0.21
  17. Ehsan Irajizad · 1 shared paper, 2026 · strength 0.21
  18. Ricardo A. Léon-Letelier · 1 shared paper, 2026 · strength 0.21
  19. Jody V. Vykoukal · 1 shared paper, 2026 · strength 0.21
  20. Yihui Chen · 1 shared paper, 2026 · strength 0.21
  21. LaNisha L. Patterson · 1 shared paper, 2026 · strength 0.21
  22. Vincent Bernard Pagan · 1 shared paper, 2026 · strength 0.21
  23. Johannes Francois Fahrmann · 1 shared paper, 2026 · strength 0.21
  24. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.21
  25. Samir Hanash · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.